Back to top
more

Cerner Corporation (CERN)

(Delayed Data from NSDQ)

$68.47 USD

68.47
2,167,881

+0.46 (0.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $68.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.

Cerner (CERN) Surpasses Q1 Earnings Estimates

Cerner (CERN) delivered earnings and revenue surprises of 5.97% and -1.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Cerner (CERN) to Report Q1 Earnings: What's in the Cards?

Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, margin contraction remains a woe.

Here's Why You Should Retain Cerner (CERN) Stock for Now

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margin remains a woe.

Cerner (CERN) Down 6.5% Since Last Earnings Report: Can It Rebound?

Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Cerner (CERN) Catches Eye: Stock Jumps 5.9%

Cerner (CERN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Cerner (CERN) Earnings and Revenues Beat Estimates in Q4

Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

Cerner (CERN) Tops Q4 Earnings and Revenue Estimates

Cerner (CERN) delivered earnings and revenue surprises of 1.35% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Here's Why You Should Hold on to OPKO Health Stock for Now

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add HealthEquity (HQY) to Portfolio Now

Solid prospects in the HSA industry consistently drive HealthEquity (HQY).

Here's Why You Should Invest in Intuitive Surgical Stock Now

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand

Intuitive Surgical (ISRG) gains from solid international show in Q4.

NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3

NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.

Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now

Veeva (VEEV) sees a slew of positive developments.

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

Allscripts Expands Partnership With PIH Health Through 2025

Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.